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Article 
When a cell multiplies, differentiates or dies it relies on a number of complex signalling 
networks. In turn, mutations in nodes that increase or decrease communication through 
these networks frequently result in diseases. An example is the Ras gene family, which is often 
mutated in cancer: activating mutations at certain Ras codons lead to cells proliferating and 
forming tumours (Prior et al., 2020). However, too much activation can trigger safety 
mechanisms and the cell dying. How much Ras activity is enough to drive cancer is therefore 
a fundamental question.  
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For a long time it was assumed that any mutation that activated Ras proteins would lead to 
disease. New evidence, however, has revealed that local cellular and disease context creates 
important differences between Ras mutants (Killoran and Smith, 2019; Haigis et al., 2019). In 
one study on mice, for example, out of twelve different mutations introduced in equal 
quantities in a Ras gene called KRAS, only five led to the animals developing lung tumours 
(Winters et al., 2017). Intriguingly, which mutation drives disease was different depending on 
the type of cancer, and the genetic background of the mouse strain. These data imply 
mutation-specific differences in Ras biology.  
 
Now, in eLife, Siqi Li and Christopher Counter from Duke University report describing the 
optimal conditions in which various Ras mutations operate (Li et al., 2018). According to a 
previously proposed ‘sweet spot’ model, there is a level of Ras activity high enough to 
promote tumour formation, but not to lead to cell death (Li and Counter, 2021). To examine 
this model, a classic mouse cancer model was exposed to urethane, a chemical found in 
fermented foods that consistently generates a codon Q61* mutation in KRAS and leads to 
Ras-driven lung cancer (Westcott et al., 2015; Dwyer-Nield et al., 2010). Codon Q61* 
mutations are known to lead to more Ras activity than codon G12* mutations (Burd et al., 
2014; Figure 1); this suggests codon Q61* mutations, rather than G12* have optimal levels of 
Ras signalling in this urethane-induced cancer model.  
 
To test if weaker G12* mutations could also induce cancer in this model, a mouse strain with 
increased KRAS expression (called KRASex3op) was exposed to urethane, artificially boosting 
the amount of active Ras. Even though Q61* mutations were still generated, G12* mutations 
were found to drive the development of tumours in these animals; this demonstrated that 
the switch was due to Ras biological properties, a result consistent with the sweet spot model.  
 
 
Whether strong Ras signalling – which would normally induce cell death – could be moved 
into the optimal activity zone was explored by deleting p53 in wild type mice. This gene 
instructs cells to die when oncogenic stress induces unrepairable DNA damage. As predicted, 
p53-/-, KRASex3op mice mouse strains with increased KRAS expression and depleted p53 could 
tolerate high levels of Q61* mutations Ras (Figure 1). Intriguingly, p53-/- mice also showed an 
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endogenous amplification of KRAS, which moved G12* mutations up into the optimal Ras 
signalling zone. This was not due to additional copies of Ras genes, but to an increase in the 
production of messenger RNAs carrying the G12* change.  
 
Together, these data reveal a narrow window of cancer-causing Ras activity; this suggests that 
the role of specific Ras mutations, and how they are combined, needs to be considered for 
research design and treatment options. However, further studies need to formally quantify 
how a range of Ras mutations and combinations differ in their relative activity. This will help 
to confirm whether the model holds true across a broader range of cancer contexts, and to 
more precisely determine optimal Ras activity. 
 
The model is based on observed endpoints – after tumours have grown. Yet, it is reasonable 
to assume that the optimal level of Ras signalling changes as the cancer develops: for instance, 
Ras alleles are amplified and lost over the life history of cancer, and in response to therapy 
(Burgess et al., 2017). An exciting observation was the increase in KRAS messenger RNA to 
help modulate Ras activity; however, this still needs to be validated by measuring Ras protein 
levels. Finally, how variable levels of Ras activity then variously impact on wider cancer 



























Figure 1. Optimal Ras signalling is required for tumour development  
Li and Counter investigated the impact of Q61* and G12* mutations in the Ras gene KRAS on 
wild-type and mutant mice. Q61* and G12* mutations respectively lead to a large and 
moderate increase in the activity of the gene. 
Wild-type mice exposed to urethane (which causes Q61* mutations) develop lung cancer 
after a year (top; first line of table). KRASex3op mutant mice have raised Ras activity, and 
therefore increased oncogenic stress; in these animals, the G12* mutation is the main driver 
of tumours, because it is less active than Q61* (second line of table). Conversely, p53-/- mice 
which have decreased oncogenic stress are able to tolerate high levels of Ras activity driven 
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by Q61* mutations, leading to tumour growth; however, they also showed increased levels 
of G12* KRAS mutant messenger RNA (third line). p53-/-, KRASex3op mutants have normal levels 
of oncogenic stress, and in these animals both Q61* and G12* mutation can lead to disease 
(fourth line). Overall, depending on the genetic background of the animal, which mutations 
lead to the level of Ras activity that triggers cancer varies (bottom).  
↑ indicate genotypes or post-transcriptional mechanisms that increase Ras abundance. 
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